Aliases & Classifications for Conjunctival Disease

MalaCards integrated aliases for Conjunctival Disease:

Name: Conjunctival Disease 12 14
Conjunctival Diseases 51 41 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4251
ICD10 32 H10-H11 H11.9
ICD9CM 34 372 372.9
MeSH 41 D003229
NCIt 46 C27605
UMLS 69 C0009759

Summaries for Conjunctival Disease

MalaCards based summary : Conjunctival Disease, also known as conjunctival diseases, is related to conjunctivitis and optic papillitis, and has symptoms including visual disturbance and eye manifestations. An important gene associated with Conjunctival Disease is IL4 (Interleukin 4), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Ethanol and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are hematopoietic system and immune system

Related Diseases for Conjunctival Disease

Diseases related to Conjunctival Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
# Related Disease Score Top Affiliating Genes
1 conjunctivitis 28.7 CCL11 IL13 IL4 IL5 MS4A2 NLRP3
2 optic papillitis 10.5 CD40LG MRAP
3 acute retinal necrosis syndrome 10.5 CD40LG MRAP
4 selective igg deficiency disease 10.5 CD40LG CD79A
5 c1q nephropathy 10.5 CD40LG CD79A
6 meningovascular neurosyphilis 10.5 CD40LG CD79A
7 alpha chain disease 10.5 CD40LG CD79A
8 brill-zinsser disease 10.5 CD40LG CD79A
9 exudative glomerulonephritis 10.5 CD40LG CD79A
10 cork-handlers' disease 10.5 CD40LG CD79A
11 salpingo-oophoritis 10.5 CD40LG CD79A
12 early yaws 10.5 CD40LG CD79A
13 ventilation pneumonitis 10.5 CD40LG CD79A
14 axillary adenitis 10.5 CD40LG CD79A
15 cryofibrinogenemia 10.5 CD40LG CD79A
16 trichostrongyloidiasis 10.5 CD40LG CD79A
17 subacute bacterial endocarditis 10.5 CD40LG CD79A
18 heterophyiasis 10.5 CD40LG CD79A
19 immunoglobulin g deficiency 10.5 CD40LG CD79A
20 orbital granuloma 10.5 CD40LG CD79A
21 transient hypogammaglobulinemia of infancy 10.5 CD40LG CD79A
22 anisakiasis 10.5 CD79A RNASE3
23 hyperglobulinemic purpura 10.4 CD40LG CD79A
24 gastroduodenitis 10.4 CD40LG CD79A
25 toxocariasis 10.4 CD40LG RNASE3
26 bacterial conjunctivitis 10.4 CD40LG CD79A
27 papillary conjunctivitis 10.4 CCL11 IL4
28 heavy chain disease 10.4 CD40LG CD79A
29 ophthalmia neonatorum 10.4 CD40LG CD79A
30 parotid disease 10.4 CD40LG CD79A
31 selective immunoglobulin deficiency disease 10.4 CD40LG CD79A
32 geniculate herpes zoster 10.4 CD40LG CD79A
33 erythema elevatum diutinum 10.4 CD40LG CD79A
34 sporotrichosis 10.4 CD40LG CD79A
35 penicillin allergy 10.4 IL13 IL4
36 fallopian tube disease 10.4 CD40LG CD79A
37 hyperimmunoglobulin syndrome 10.4 CD40LG CD79A
38 congenital syphilis 10.4 CD40LG CD79A
39 polyclonal hypergammaglobulinemia 10.4 CD40LG CD79A
40 african tick-bite fever 10.4 CD40LG IL13
41 monoclonal paraproteinemia 10.4 CD40LG CD79A
42 acute conjunctivitis 10.4 PLD3 PSEN2
43 acute hemorrhagic conjunctivitis 10.4 PLD3 PSEN2
44 salpingitis 10.4 CD40LG CD79A
45 ocular toxoplasmosis 10.4 CD40LG CD79A
46 giant papillary conjunctivitis 10.4 CCL11 IL4
47 dysgammaglobulinemia 10.4 CD40LG CD79A
48 acute maxillary sinusitis 10.4 CD40LG CD79A
49 blepharoconjunctivitis 10.4 CCL11 IL4 RNASE3
50 tolosa-hunt syndrome 10.4 CD40LG NLRP3

Graphical network of the top 20 diseases related to Conjunctival Disease:



Diseases related to Conjunctival Disease

Symptoms & Phenotypes for Conjunctival Disease

UMLS symptoms related to Conjunctival Disease:


visual disturbance, eye manifestations

MGI Mouse Phenotypes related to Conjunctival Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 PSEN2 IL5 IL6ST MS4A2 CCL11 NLRP3
2 immune system MP:0005387 9.93 PSEN2 IL5 IL6ST MS4A2 CCL11 NLRP3
3 digestive/alimentary MP:0005381 9.87 IL4 PSEN2 IL5 IL6ST NLRP3 IL13
4 integument MP:0010771 9.56 IL4 PSEN2 IL6ST NLRP3 CD40LG PHB2
5 reproductive system MP:0005389 9.23 IL4 IL5 IL6ST NLRP3 CD40LG PHB2

Drugs & Therapeutics for Conjunctival Disease

Drugs for Conjunctival Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 368)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
3
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
4
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
5
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
6
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2 82410-32-0 3454
7
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 9004-61-9 53477741 24759
8
Glycerol Approved, Investigational Phase 4,Phase 3,Phase 2 56-81-5 753
9
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 51-45-6, 75614-87-8 774
10
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 299-42-3 9294
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
12
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 2 35189-28-7 6540478
13
Tobramycin Approved, Investigational Phase 4,Phase 3 32986-56-4 36294 5496
14
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1 82419-36-1 4583
15
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 151096-09-2, 354812-41-2 152946
16
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-82-4 7028
17
Loteprednol Approved Phase 4,Phase 3,Phase 2 129260-79-3, 82034-46-6 9865442 444025
18
Gatifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 112811-59-3 5379
19
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
20
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
21
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
22
Dipivefrin Approved Phase 4,Phase 3,Phase 2 52365-63-6 3105
23
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100986-85-4 149096
24
Pheniramine Approved Phase 4 86-21-5 4761
25
Naphazoline Approved Phase 4,Phase 3 835-31-4 4436
26
Povidone Approved Phase 4,Phase 3 9003-39-8
27
Montelukast Approved Phase 4 158966-92-8 5281040
28
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 46936176 6474909
29
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
30
Iodine Approved, Investigational Phase 4,Phase 3 7553-56-2 807
31
Ketotifen Approved Phase 4,Phase 3,Phase 2,Phase 1 34580-13-7, 34580-14-8 3827
32
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 83905-01-5 53477736 447043 55185
33
Ketorolac Approved Phase 4,Phase 2,Phase 3 74103-06-3, 66635-83-4 3826
34
Tranilast Approved, Investigational Phase 4,Phase 3 53902-12-8 93543
35
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
36
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
37
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
38
Desloratadine Approved, Investigational Phase 4,Phase 3 100643-71-8 124087
39
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
40
Epinastine Approved, Investigational Phase 4,Phase 3 80012-43-7 3241
41
Menthol Approved Phase 4 2216-51-5 16666
42
Albendazole Approved, Vet_approved Phase 4 54965-21-8 2082
43
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
44
Povidone-iodine Approved Phase 4,Phase 3 25655-41-8
45
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
46
Dimenhydrinate Approved Phase 4 523-87-5 441281
47
Sorbitol Approved Phase 4 50-70-4 5780
48
Fluorouracil Approved Phase 4 51-21-8 3385
49
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 68-26-8, 11103-57-4 445354
50
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2

Interventional clinical trials:

(show top 50) (show all 874)

# Name Status NCT ID Phase Drugs
1 Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count. Unknown status NCT02641132 Phase 4 Mitomycin C 0.02%
2 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4 Alcaftadine
3 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
4 The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
5 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
6 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
7 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
8 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
9 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
10 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
11 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
12 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
13 A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome Unknown status NCT00344721 Phase 4 Essential fatty acid supplement
14 Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management Completed NCT01736449 Phase 4 Bevacizumab
15 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4 loteprednol etabonate and tobramycin;loteprednol etabonate;Tobramycin;Vehicle of Zylet
16 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4 moxifloxacin;polytrim
17 Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia Completed NCT00383396 Phase 4 Topical Cyclosporine
18 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
19 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
20 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
21 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
22 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
23 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
24 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
25 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
26 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
27 Tolerability of Grazax in Patients With Hayfever in Real Life Settings Completed NCT01433510 Phase 4 Grazax
28 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
29 Assessment of Alcon's Ocular Image Quantification System Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
30 A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
31 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
32 Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
33 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
34 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
35 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
36 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Artificial tears
37 A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
38 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
39 A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Completed NCT00311844 Phase 4 desloratadine
40 Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
41 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
42 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
43 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
44 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
45 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
46 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
47 The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease Completed NCT02120079 Phase 4 Lotemax;Artificial Tears
48 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
49 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
50 A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Completed NCT01014078 Phase 4 Azithromycin Ophthalmic Solution, 1%;Placebo

Search NIH Clinical Center for Conjunctival Disease

Cochrane evidence based reviews: conjunctival diseases

Genetic Tests for Conjunctival Disease

Anatomical Context for Conjunctival Disease

MalaCards organs/tissues related to Conjunctival Disease:

38
Eye, Testes, Skin, B Cells, Endothelial, Salivary Gland, Bone

Publications for Conjunctival Disease

Articles related to Conjunctival Disease:

(show all 12)
# Title Authors Year
1
Age-related conjunctival disease in the C57BL/6.NOD-Aec1Aec2 Mouse Model of SjAPgren Syndrome develops independent of lacrimal dysfunction. ( 25758816 )
2015
2
Skin Prick Test Reactivity to Aeroallergens among Egyptian Patients with Isolated Allergic Conjunctival Disease. ( 28502143 )
2015
3
Evaluation of total and allergen-specific secretory IgA in tears of allergic conjunctival disease patients. ( 17926109 )
2007
4
Concentration of soluble interleukin-6 receptors in tears of allergic conjunctival disease patients. ( 17926108 )
2007
5
Evaluation of ocular surface inflammation in the presence of dry eye and allergic conjunctival disease. ( 17216110 )
2005
6
Elevated levels of human alpha -defensin in tears of patients with allergic conjunctival disease complicated by corneal lesions: detection by SELDI ProteinChip system and quantification. ( 16123017 )
2005
7
Predominance of infiltrating IL-4-producing T cells in conjunctiva of patients with allergic conjunctival disease. ( 15590468 )
2004
8
Tarsal-conjunctival disease associated with Wegener's granulomatosis. ( 13129876 )
2003
9
[Topical Fk506 in inflammatory corneal and conjunctival diseases. A pilot study]. ( 11987039 )
2002
10
Tear osteopontin levels in patients with allergic conjunctival diseases. ( 12486515 )
2002
11
Impression Cytology with Transfer in xerophthalmia and conjunctival diseases. ( 1490836 )
1992
12
Silver preparations in conjunctival disease. ( 16692078 )
1906

Variations for Conjunctival Disease

Expression for Conjunctival Disease

Search GEO for disease gene expression data for Conjunctival Disease.

Pathways for Conjunctival Disease

Pathways related to Conjunctival Disease according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 CCL11 CD40LG CD79A IL13 IL4 IL5
2
Show member pathways
13.16 CCL11 CD40LG IL13 IL4 IL5 PLD3
3
Show member pathways
12.45 IL13 IL4 IL5 IL6ST
4
Show member pathways
12.44 CD79A IL13 IL4 IL5 MS4A2
5 12.41 CD40LG CD79A IL4 IL6ST
6
Show member pathways
12.22 IL13 IL4 IL5 IL6ST
7
Show member pathways
12.13 CCL11 IL13 IL4 IL5 IL6ST
8
Show member pathways
12.01 IL13 IL4 IL5
9
Show member pathways
11.91 CCL11 CD40LG IL13 IL4 IL5 MS4A2
10 11.85 CD79A IL4 IL5
11 11.83 CCL11 IL13 IL4
12 11.67 IL13 IL4 IL5
13 11.65 IL13 IL4 IL5
14
Show member pathways
11.61 CD40LG IL4 IL5
15 11.54 CD40LG IL4 IL5
16 11.42 CCL11 CD40LG IL4 IL5
17 11.36 CCL11 IL13 IL4 IL5
18 11.19 CD40LG IL4 IL5
19 11.16 IL13 IL4 IL5
20 11.11 IL13 IL4 IL5
21 11.02 IL13 IL4 IL5
22 11 CCL11 CD40LG IL13 IL4 IL5
23 10.92 CCL11 IL13 IL4 IL5
24 10.9 CCL11 IL6ST
25 10.88 CCL11 CD40LG IL13 IL4 IL5
26 10.41 IL13 IL4 IL5

GO Terms for Conjunctival Disease

Cellular components related to Conjunctival Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 CCL11 CD40LG IL13 IL4 IL5 PLG
2 extracellular region GO:0005576 9.61 CCL11 CD40LG IL13 IL4 IL5 IL6ST
3 external side of plasma membrane GO:0009897 9.02 CD40LG CD79A IL13 IL6ST MS4A2

Biological processes related to Conjunctival Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.85 CD40LG IL4 IL6ST PHB2 PSEN2
2 regulation of receptor activity GO:0010469 9.72 CCL11 CD40LG IL13 IL4 IL5
3 B cell differentiation GO:0030183 9.58 CD40LG CD79A IL4
4 positive regulation of T cell proliferation GO:0042102 9.54 CD40LG IL4 IL6ST
5 positive regulation of interleukin-4 production GO:0032753 9.48 CD40LG NLRP3
6 positive regulation of interleukin-13 production GO:0032736 9.43 IL4 NLRP3
7 positive regulation of B cell proliferation GO:0030890 9.43 IL13 IL4 IL5
8 immune response GO:0006955 9.43 CCL11 CD40LG IL13 IL4 IL5 MS4A2
9 negative regulation of complement-dependent cytotoxicity GO:1903660 9.16 IL13 IL4
10 inflammatory response GO:0006954 9.1 CCL11 CD40LG IL13 IL5 MS4A2 NLRP3

Molecular functions related to Conjunctival Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 CCL11 CD40LG IL13 IL4 IL5

Sources for Conjunctival Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....